‘InnoPharma, Inc is now a wholly owned subsidiary of Pfizer, Inc’

DOWNLOAD PDF -  Piscataway, N.J., August 29, 2014 – InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.’s DACOGEN®.

DOWNLOAD PDF  –  Piscataway, N.J., July 30, 2014 – InnoPharma, Inc. today announced the first generic launch of Olanzapine for Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada. Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania.

As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada.

DOWNLOAD PDF  – NEW YORK, N.Y., and PISCATAWAY, NJ, July 16 – Pfizer Inc. (NYSE: PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma.

Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

DOWNLOAD PDF – Piscataway, N.J., January 6, 2014 – InnoPharma, Inc., a privately held company focused on developing first to file and first to market opportunities in the complex generic and specialty pharmaceutical product space, is pleased to announce that it is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference at 8:00 am PT on January 15, 2014. The conference will be held at the Westin St. Francis Hotel in San Francisco.

DOWNLOAD PDF – PISCATAWAY, N.J., November 13, 2013 — InnoPharma, Inc today announced that it has closed on a $20 million term loan facility, provided by Athyrium Capital Management through its Athyrium Opportunities Fund. Proceeds will support the Company’s ongoing development of complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. Armentum Partners acted as financial advisors to InnoPharma for this transaction.

DOWNLOAD PDF – PISCATAWAY, N.J., Nov. 11, 2013 — InnoPharma, Inc. today announced the appointment of Vish Shetty to the role of vice president, business development & alliance management. Mr. Shetty has over 10 years of extensive experience in market research, portfolio management, marketing, product launches, business development and strategic planning with pharmaceutical companies.

DOWNLOAD PDF – PISCATAWAY, N.J., Aug. 15, 2013 — InnoPharma, Inc. today announced the launch of acamprosate calcium, 333 mg delayed-release tablets (generic equivalent of Campral®). InnoPharma developed the generic formulation of acamprosate delayed-release tablets and entered into an agreement with Glenmark Pharmaceuticals, Inc. pursuant to which Glenmark will sell, market and distribute acamprosate in the United States.


A balanced business model that consists of a successful generic business and a specialty pharmaceutical strategy to drive higher long-term growth.

Learn More

FeaturedProductsImage5Marketed Products

Product launches are driving growth for reinvestment into the company and confirming successful product selection with limited competition at launch.

Learn More